The results from new clinical trials offer evidence that a high-dosage of immunosuppressive medication followed by replacement of an individual’s blood-making stem cell can trigger permanent remission of multiple sclerosis (MS), a severe autoimmune disease whereby the immune system fights the central nervous system. A half a decade after being treated with high-dose immunosuppressive therapy plus autologous hematopoietic cell transplant, 69 percent of clinical trial members did not experience any progression of disability, new brain lesions, or MS symptoms’ relapse. Several studies have established that the approved MS medications have minimal success rates.
The National Institute of Allergy and Infectious Disease (NIAID) sponsored this clinical trial, which was carried out by the Immune Tolerance Network. The team of experienced researchers released three-year results of the trial in December 2014 and published the final five-year results in Neurology on February 1, 2017. Neurology is an established medical journal owned by the American Academy of Neurology. According to Anthony Fauci, the managing director of NIAID, HDIT/HCT treatment may be more efficient than the currently available therapies for individuals with a particular type of MS. The results show that most participants in the trial remained in stable conditions five years after receiving HDIT/HCT treatment.
About Dr. Shiva Gopal
Dr. Shiva Gopal is an accomplished neurologist based in Voorhees, NJ. He earned his medical degree from the Government Medical College back in 1979. Dr. Shiva has served as a physician for over four decades.
Currently, Dr. Shiva Gopal offers his medical services to the Eastern Neurodiagnostic Associates’ clients. He is also allied to the Kennedy Health System Cherry Hill Campus. He accepts several insurance programs such as Horizon Blue, Aetna, Medicare, and Cross Blue Shield. Dr. Shiva Gopal is fluent in English and Spanish.